Sen. Elizabeth Warren demanded access to Trump-era drug-pricing contracts, accusing RFK Jr. of hiding details. The call centers on transparency around contract terms and the underlying basis for pricing decisions in the U.S. drug market. The development matters for biotech because contract language can directly shape market access, reimbursement outcomes, and the speed at which negotiated pathways translate into measurable adoption by payers and providers. The dispute also sits alongside broader regulatory momentum on how early clinical evidence is built and reviewed, suggesting that policy attention is simultaneously moving upstream (trial start timelines) and downstream (pricing and contracting). For companies, the actionable takeaway is that contract scrutiny is likely to remain a near-term risk factor affecting strategy around partnerships, pricing models, and patient access initiatives.